[1] International Conference on Harmonization. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1) (Step 4 version)[EB/OL]. (2011-11-09)[2016-4-11]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf.;
[2] IIDA Y, TAKEDA J, MIYATA T, et al. Characterization of genomic PIG-A gene:a gene for glycosylphosphatidylinositol-anchor biosynthesis and paroxysmal nocturnal hemoglobinuria[J]. Blood, 1994, 83(11):3126-3131.;
[3] KAWAGOE K, KITAMURA D, OKABE M, et al. Glycosylphosphatidylinositol-anchor-deficient mice:implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria[J]. Blood, 1996, 87(9):3600-3606.;
[4] KAWAGOE K, TAKEDA J, ENDO Y, et al. Molecular cloning of murine pig-a, a gene for GPI-anchor biosynthesis, and demonstration of interspecies conservation of its structure, function, and genetic locus[J]. Genomics, 1994, 23(3):566-574.;
[5] TAKEDA J, MIYATA T, KAWAGOE K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria[J]. Cell, 1993, 73(4):703-711.;
[6] ARATEN D J, NAFA K, PAKDEESUWAN K, et al. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals[J]. Proc Natl Acad Sci USA, 1999, 96(9):5209-5214.;
[7] BRYCE S M, BEMIS J C, DERTINGER S D. In vivo mutation assay based on the endogenous Pig-a locus[J]. Environ Mol Mutagen, 2008, 49(4):256-264.;
[8] MIURA D, DOBROVOLSKY V N, KASAHARA Y, et al. Development of an in vivo gene mutation assay using the endogenous Pig-A gene:I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat[J]. Environ Mol Mutagen, 2008, 49(8):614-621.;
[9] MIURA D, DOBROVOLSKY V N, MITTELSTAEDT R A, et al. Development of an in vivo gene mutation assay using the endogenous Pig-A gene:II. Selection of Pig-A mutant rat spleen T-cells with proaerolysin and sequencing Pig-A cDNA from the mutants[J]. Environ Mol Mutagen, 2008, 49(8):622-630.;
[10] DOBROVOLSKY V N, MIURA D, HEFLICH R H, et al. The in vivo Pig-a gene mutation assay, a potential tool for regulatory safety assessment[J]. Environ Mol Mutagen, 2010, 51(8/9):825-835.;
[11] GOLLAPUDI B B, LYNCH A M, HEFLICH R H, et al. The in vivo pig-a assay:A report of the international workshop on genotoxicity testing (IWGT) workgroup[J]. Mutat Res Genet Toxicol Environ Mutagen, 2015, 783:23-35.;
[12] DOBROVOLSKY V N, SHADDOCK J G, MITTELSTAEDT R A, et al. Evaluation of Macaca mulatta as a model for genotoxicity studies[J]. Mutat Res Toxicol Environ Mutagen, 2009, 673(1):21-28.;
[13] PHONETHEPSWATH S, FRANKLIN D, TOROUS D K, et al. Pig-a mutation:kinetics in rat erythrocytes following exposure to five prototypical mutagens[J]. Toxicol Sci, 2010, 114(1):59-70.;
[14] DOBROVOLSKY V N, BOCTOR S Y, TWADDLE N C, et al. Flow cytometric detection of Pig-A mutant red blood cells using an erythroid-specific antibody:application of the method for evaluating the in vivo genotoxicity of methylphenidate in adolescent rats[J]. Environ Mol Mutagen, 2010, 51(2):138-145.;
[15] CHEN G F, WEN H R, MAO Z H, et al. Assessment of the Pig-a, micronucleus, and comet assay endpoints in rats treated by acute or repeated dosing protocols with procarbazine hydrochloride and ethyl carbamate[J]. Environ Mol Mutagen, 2019, 60(1):56-71.;
[16] NISHIMURA J, MURAKAMI Y, KINOSHITA T. Paroxysmal nocturnal hemoglobinuria:An acquired genetic disease[J]. Am J Hematol, 1999, 62(3):175-182.;
[17] ALBERTINI R J. PIG-A as a reporter gene for somatic mutations in humans[J]. Environ Mol Mutagen, 2008, 49(7):539.;
[18] PARKER M W, VAN DER GOOT F G, BUCKLEY J T. Aerolysin:the ins and outs of a model channel-forming toxin[J]. Mol Microbiol, 1996, 19(2):205-212.;
[19] MIURA D, DOBROVOLSKY V N, KIMOTO T, et al. Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosourea[J]. Mutat Res, 2009, 677(1/2):86-92.;
[20] DERTINGER S D, PHONETHEPSWATH S, FRANKLIN D, et al. Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies[J]. Toxicol Sci, 2010, 115(2):401-411.;
[21] YOSHIDA I, MATSUMOTO A, SAKAI Y M, et al. Pyrene did not induce gene mutation in red blood cell Pig-a assay and PIGRET assay in rats[J]. Mutation Research/Genetic Toxicology And Environmental Mutagenesis, 2016, 811:49-53.;
[22] GOLLAPUDI B B, LYNCH A M, HEFLICH R H, et al. The in vivo pig-a assay:A report of the international workshop on genotoxicity testing (IWGT) workgroup[J]. Mutat Res Genet Toxicol Environ Mutagen, 2015, 783:23-35.;
[23] DERTINGER S D, PHONETHEPSWATH S, AVLASEVICH S L, et al. Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage:summary of 7 published studies and results from 11 new reference compounds[J]. Toxicol Sci, 2012, 130(2):328-348.;
[24] MIURA D, DOBROVOLSKY V, HEFLICH R. Molecular aspects and potential advantages of Pig-A gene high throughput assay in the rat[J]. Environ Mol Mutagen, 2008, 49(7):539.;
[25] LEMIEUX C L, DOUGLAS G R, GINGERICH J, et al. Simultaneous measurement of benzo[a]pyrene-induced Pig-a and lacZ mutations, micronuclei and DNA adducts in MutaTM Mouse[J]. Environ Mol Mutagen, 2011, 52(9):756-765.;
[26] DERTINGER S D, PHONETHEPSWATH S, WELLER P, et al. International Pig-a gene mutation assay trial:evaluation of transferability across 14 laboratories[J]. Environ Mol Mutagen, 2011, 52(9):690-698.;
[27] CAMMERER Z, BHALLI J A, CAO X F, et al. Report on stage III Pig-a mutation assays using N-ethyl-N-nitrosourea-comparison with other in vivo genotoxicity endpoints[J]. Environ Mol Mutagen, 2011, 52(9):721-730.;
[28] LYNCH A M, GIDDINGS A, CUSTER L, et al. International Pig-a gene mutation assay trial (stage III):results with N-methyl-N-nitrosourea[J]. Environ Mol Mutagen, 2011, 52(9):699-710.;
[29] STANKOWSKI L F Jr, ROBERTS D J, CHEN H P, et al. Integration of Pig-a, micronucleus, chromosome Aberration and Comet assay endpoints in a 28-day rodent toxicity study with 4-nitroquinoline-1-oxide[J]. Environ Mol Mutagen, 2011, 52(9):738-747.;
[30] DERTINGER S D, BRYCE S M, PHONETHEPSWATH S, et al. When pigs fly:immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysis[J]. Mutat Res, 2011, 721(2):163-170.;
[31] DERTINGER S D, PHONETHEPSWATH S, WELLER P, et al. Interlaboratory Pig-a gene mutation assay trial:Studies of 1, 3-propane sultone with immunomagnetic enrichment of mutant erythrocytes[J]. Environ Mol Mutagen, 2011, 52(9):748-755.;
[32] PU J, DENG Y Y, TAN X Y, et al. The in vivo Pig-a gene mutation assay is applied to study the genotoxicity of procarbazine hydrochloride in Sprague-Dawley rats[J]. Fundam Toxicol Sci, 2016, 3(4):167-175.;
[33] KRüGER C T, HOFMANN M, HARTWIG A. The in vitro PIG-A gene mutation assay:mutagenicity testing via flow cytometry based on the glycosylphosphatidylinositol (GPI) status of TK6 cells[J]. Arch Toxicol, 2015, 89(12):2429-2443.;
[34] KRüGER C T, FISCHER B M, ARMANT O, et al. The in vitro PIG-A gene mutation assay:glycosylphosphatidylinositol (GPI)-related genotype-to-phenotype relationship in TK6 cells[J]. Arch Toxicol, 2016, 90(7):1729-1736.;
[35] DAVID R, TALBOT E, ALLEN B, et al. The development of an in vitro Pig-a assay in L5178Y cells[J]. Arch Toxicol, 2018, 92(4):1609-1623.;
[36] REES B J, TATE M, LYNCH A M, et al. Development of anin vitro PIG-A gene mutation assay in human cells[J]. Mutagenesis, 2017:gew059.;
[37] International Conference on Harmonization. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk[EB/OL]. (2017-07-21)[2018-02-03]. https://www.ema.europa.eu/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf |
